The Role of DLBS3233 in the Management of Polycystic Ovary Syndrome (PCOS)
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2018
Price : $35 *
At a glance
- Drugs DLBS 3233 (Primary) ; Metformin
- Indications Polycystic ovary syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Dexa Medica
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2018 Status changed from recruiting to completed.
- 23 Nov 2017 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.